Registration gives the benefit of site update e-mails and additional information from Takeda on new education materials and events.
ADHD Institute Register
Home | Meetings & events » On-demand events » Webinar: Adult ADHD and comorbid substance-use disorder

The ‘Adult ADHD and comorbid substance-use disorder’ webinar was hosted by Dr Peter Mason (Cheshire & Wirral Partnership NHS Foundation Trust, Birkenhead, UK) on Monday 17th September 2018. He was joined on this webinar by Professor Toni Ramos (Vall d’Hebron University Hospital, Barcelona, Spain) for a highly informative interactive patient case study discussion.

These webinars may in part reflect the personal experiences and opinions of the presenters. Treatment-related statements do not necessarily reflect Takeda's position nor are they necessarily in line with the approved labels in all countries.


Question 1 (of 4)

In a Spanish observational study by Piñeiro-Dieguez et al (2016), which investigated psychiatric comorbidity at the time of adult ADHD diagnosis in 367 patients, the prevalence of comorbid substance-use disorder in adults with ADHD was:

Please select one of the following

25.3%
31.3%
39.2%
45.2%

Question 2 (of 4)

In a multinational cross‑sectional European study by Deberdt et al (2015), the prevalence of comorbid ADHD among 349 adults with substance dependence was:

Please select one of the following

12.8%
27.1%
24.4%
30.8%

Question 3 (of 4)

In a study by Halmøy et al (2009), which compared outcomes in 414 adults with ADHD by treatment status during childhood (treated vs untreated), patients who were treated during childhood had:

Please select one of the following

A higher prevalence of problems with drugs other than alcohol
A lower prevalence of problems with alcohol, but a similar prevalence of problems with drugs other than alcohol
A lower prevalence of problems with drugs other than alcohol, but a similar prevalence of problems with alcohol
A similar prevalence of problems with drugs other than alcohol

Question 4 (of 4)

In a study by Bihlar Muld et al, which investigated long-term outcomes by treatment status (treated vs untreated) in 60 adult male patients with ADHD and comorbid severe substance use disorder, treated patients had:

Please mark all that apply

Lower mortality and substance use and better occupational outcomes amongst treated adults
Lower substance use relapses, better occupational outcomes and no effect on mortality amongst treated adults
Treatment had no effect on mortality, substance use or occupational outcomes
Lower substance use but no effect on mortality or occupational outcomes in treated adults

Question 1 (of 4)

In a Spanish observational study by Piñeiro-Dieguez et al (2016), which investigated psychiatric comorbidity at the time of adult ADHD diagnosis in 367 patients, the prevalence of comorbid substance-use disorder in adults with ADHD was:

Please select one of the following

25.3%
31.3%
39.2%
45.2%

Question 2 (of 4)

In a multinational cross‑sectional European study by Deberdt et al (2015), the prevalence of comorbid ADHD among 349 adults with substance dependence was:

Please select one of the following

12.8%
27.1%
24.4%
30.8%

Question 3 (of 4)

In a study by Halmøy et al (2009), which compared outcomes in 414 adults with ADHD by treatment status during childhood (treated vs untreated), patients who were treated during childhood had:

Please select one of the following

A higher prevalence of problems with drugs other than alcohol
A lower prevalence of problems with alcohol, but a similar prevalence of problems with drugs other than alcohol
A lower prevalence of problems with drugs other than alcohol, but a similar prevalence of problems with alcohol
A similar prevalence of problems with drugs other than alcohol

Question 4 (of 4)

In a study by Bihlar Muld et al, which investigated long-term outcomes by treatment status (treated vs untreated) in 60 adult male patients with ADHD and comorbid severe substance use disorder, treated patients had:

Please mark all that apply

Lower mortality and substance use and better occupational outcomes amongst treated adults
Lower substance use relapses, better occupational outcomes and no effect on mortality amongst treated adults
Treatment had no effect on mortality, substance use or occupational outcomes
Lower substance use but no effect on mortality or occupational outcomes in treated adults

Date of preparation: March 2021; Job code: C-ANPROM/EUC/NBU/0005

Filter content by:

Meeting of Minds XII, 27 October to 23 November 2020

Reports covering key ADHD topics discussed at Meeting of Minds XII are available now

33rd European Clinical Neuropsychopharmacology (ECNP) Virtual Congress

The 33rd European Clinical Neuropsychopharmacology Congress covered key topics and issues in ADHD

28th European Congress of Psychiatry (EPA) Virtual Congress

The 28th European Congress of Psychiatry in Madrid was transformed into a fully virtual meeting for 2020

Registration

Healthcare professional registration

Registration gives the benefit of site update e-mails and additional information from Takeda on new education materials and events.

Rating scales

Rating scales are an essential part of ADHD assessment and diagnosis for people of all ages. Clinician, parent, teacher and self-reporting scales are available

Animation: Adult ADHD and the brain

Guidelines

Evidence-based or consensus-driven guidelines for the treatment of ADHD help consolidate practice internationally

Animation: Childhood/Adolescent ADHD and the brain


ADHD Institue logo

You’re now being transferred to

and are leaving the ADHD Institute site

Takeda has no influence or control over the content of this third party website.

Continue Cancel